IRLAB Therapeutics, a Swedish biopharmaceutical company focused on Parkinson’s disease, will take part in Life Science Day on March 4, 2026, in Gothenburg. The event offers investors and industry professionals a chance to hear directly from company leadership. Gustaf Albèrt, CFO of IRLAB, will represent the organization during a presentation scheduled at 10:45 a.m. A Q&A session will follow immediately after.
Event Details: Date, Venue, and Access
Life Science Day 2026 will take place at the Wallenberg Conference Center, Sahlgrenska Academy, located at Medicinareberget in Gothenburg, Sweden. Additionally, the presentation will stream live on the official event website After the event, IRLAB’s presentation will also be available on YouTube for those who cannot attend in real time.
H3: Who Organizes Life Science Day?
Life Science Day is organized by Finwire, a media agency, in partnership with Företagsfinansiering Fyrstad. Together, they spotlight the depth and breadth of companies active across Sweden’s life science sector. The event serves as a key platform for companies to communicate their progress to a wider audience of investors and healthcare stakeholders.
About IRLAB Therapeutics
IRLAB Therapeutics (Nasdaq Stockholm: IRLAB-A) is a Gothenburg-based pharmaceutical company with a singular focus: developing transformative therapies for Parkinson’s disease. The company traces its roots to the research group of Nobel Laureate Professor Arvid Carlsson, whose pioneering work uncovered the link between brain neurotransmitter disruptions and neurological diseases. That scientific legacy continues to drive IRLAB’s innovation today.
What Is IRLAB’s Core Mission?
IRLAB’s mission centers on addressing unmet medical needs across all stages of Parkinson’s disease. Rather than targeting a single symptom, IRLAB builds a diversified portfolio designed to cover the full spectrum of disease progression. This broad approach distinguishes the company from many competitors in the neurology space.
The Integrative Screening Process (ISP) Platform
IRLAB generates its entire pipeline through its proprietary research platform known as the Integrative Screening Process, or ISP. This systems biology-based approach enables the company to identify novel drug candidates more efficiently. As a result, IRLAB has built a robust and differentiated clinical pipeline that extends from early discovery all the way to late-stage clinical trials.
IRLAB’s Parkinson’s Disease Pipeline
IRLAB maintains one of the most comprehensive Parkinson’s-focused pipelines in Europe. The company currently advances multiple programs across different stages of development.
Late-Stage Clinical Programs
Mesdopetam (IRL790) targets levodopa-induced dyskinesias (LID), a debilitating side effect that many Parkinson’s patients experience from long-term levodopa therapy. Mesdopetam has successfully completed Phase IIb and is now in preparation for Phase III trials. Furthermore, Pirepemat (IRL752) is currently in Phase IIb evaluation. Specifically, this compound targets fall frequency in Parkinson’s disease patients — an area of critical concern for patient safety and quality of life.
Early-Stage and Preclinical Programs
Beyond its lead candidates, IRLAB also advances earlier-stage assets. IRL757 is in Phase Ib and targets apathy in neurodegenerative disorders. In addition, two preclinical programs — IRL942 and IRL1117 — are progressing toward Phase I studies. Consequently, IRLAB’s pipeline reflects a sustained commitment to addressing the full complexity of Parkinson’s disease at multiple therapeutic angles.
Why This Event Matters for the Life Science Sector
Life Science Day provides an important platform for companies like IRLAB to engage with investors, analysts, and healthcare professionals in a structured format. For IRLAB, the timing is especially significant. With Mesdopetam moving toward Phase III and multiple programs advancing in parallel, the company has compelling updates to share. Moreover, events like this strengthen Sweden’s position as a global hub for life science innovation. Gothenburg, in particular, hosts a thriving cluster of pharmaceutical and biotech companies, making such gatherings a vital part of the region’s health innovation ecosystem.
Conclusion
IRLAB Therapeutics’ participation in Life Science Day 2026 underscores the company’s momentum and growing pipeline. From its Nobel Prize-rooted origins to a diverse portfolio of Parkinson’s therapies, IRLAB continues to advance science that matters. Whether you are an investor, a healthcare professional, or simply interested in the future of neurological medicine, IRLAB’s March 4 presentation is well worth following — live or on demand.
